Johnson & Johnson committed more than $1 billion to build a cell‑therapy manufacturing site in Pennsylvania, positioning the company to scale autologous and allogeneic production for next‑generation cell therapies. J&J said the investment supports its broader cell therapy strategy and manufacturing resiliency. Separately, Lonza expanded advanced synthesis and bioconjugate capabilities at its Oss, Netherlands site, integrating GlycoConnect, HydraSpace and toxSYN linker‑payload technologies to accelerate ADC and bioconjugate development and scale‑up. Lonza’s end‑to‑end offering now includes dual‑payload ADC capabilities and pilot toxicology supply. Together these moves underline industry momentum to de‑risk commercial manufacturing for complex biologics and ADCs, with large pharma and CDMOs investing to shorten time to clinic and support global launches.